Galderma
GALD · SIX · Switzerland
Public Market Listing
GALDSIX
Live quotes, historical charts, and market capitalization for Galderma are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
nemolizumab(Nemluvio) | Approved | IL-31 receptor AMonoclonal antibody | Atopic DermatitisPrurigo Nodularis |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Est. primary completion 2026-12 · NCT07074977 · CT.gov ↗
What to watch
2027 (1)
October 2027 (1)
Est. primary completion 2027-10-28 · NCT07762833 · CT.gov ↗
What to watch
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-H1 | $3.1B | — | — | — | report ↗ |